ugichem is developing antisense drugs based on its proprietary Ugimer® platform for unmet medical needs in immune-mediated inflammatory diseases (IMID).
Ugimers allow overcoming the shortcomings of standard antisense technologies or RNAi since they are not derived from natural nucleic acids. Ugimers are based on the PNA backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.